One of the biggest treatment-related fears surrounding chemotherapy is nausea and vomiting. A previous departmental audit revealed the incidence of chemotherapy-induced nausea and vomiting (CINV) during fluorouracil-leucovorin-oxaliplatin (FOLFOX) treatment with 5HT3-antagonist/dexamethasone pre-medication was 90.1%.
The primary aim was to assess the incidence of breakthrough-CINV in patients receiving triple-therapy prophylaxis (with netupitant/dexamethasone/palonosetron) versus historical control data in those-receiving 5HT3-dexamethasone prophylaxis with FOLFOX chemotherapy.
A single-centre retrospective analysis was performed, comparing the rates of breakthrough-CINV with triple-therapy prophylaxis versus historical control data in those receiving 5HT3-dexamethasone prophylaxis with FOLFOX. Patient data, treatment details and outcomes were extracted using Mosaiq®, an institutional electronic database.
Significance of the association between two categorial variables was assessed by Fisher’s exact test, with P-values being two-sided and levels of significance defined as P < 0.05. Statistical analysis was performed using SPSS software.